Cybin to Attend the Jefferies Global Healthcare Conference in London

Company Presentation: Cybin Inc. will have its Chief Business Officer, George Tziras, present at the Jefferies Global Healthcare Conference in London from November 17-20, 2025, with a live webcast scheduled for November 17 at 12:30 p.m. GMT.

Innovative Mental Healthcare: Cybin is a Phase 3 clinical-stage neuropsychiatry company focused on developing next-generation treatments for mental health conditions, including major depressive disorder and generalized anxiety disorder.

Drug Development: The company is advancing its proprietary drugs, including CYB003, a deuterated psilocin analog for major depressive disorder, and CYB004, a deuterated N,N-dimethyltryptamine molecule for generalized anxiety disorder.

Global Operations: Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland, aiming to address the significant unmet needs in mental health treatment.